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Abstract
Background: Airflow obstruction, which encompasses several phenotypes, is common among HIV-infected
individuals. Obesity and adipose-related inflammation are associated with both COPD (fixed airflow obstruction) and
asthma (reversible airflow obstruction) in HIV-uninfected persons, but the relationship to airway inflammation and
airflow obstruction in HIV-infected persons is unknown. The objective of this study was to determine if adiposity
and adipose-associated inflammation are associated with airway obstruction phenotypes in HIV-infected persons.
Methods: We performed a cross-sectional analysis of 121 HIV-infected individuals assessed with pulmonary function
testing, chest CT scans for measures of airway wall thickness (wall area percent [WA%]) and adipose tissue volumes
(mediastinal and subcutaneous), as well as HIV- and adipose-related inflammatory markers. Participants were
defined as COPD phenotype (post-bronchodilator FEV1/FVC < lower limit of normal) or asthma phenotype (doctor-
diagnosed asthma or bronchodilator response). Pearson correlation coefficients were calculated between adipose
measurements, WA%, and pulmonary function. Multivariable logistic and linear regression models were used to
determine associations of airflow obstruction and airway remodeling (WA%) with adipose measurements and
participant characteristics.
Results: Twenty-three (19 %) participants were classified as the COPD phenotype and 33 (27 %) were classified as
the asthma phenotype. Body mass index (BMI) was similar between those with and without COPD, but higher in
those with asthma compared to those without (mean [SD] 30.7 kg/m2 [8.1] vs. 26.5 kg/m2 [5.3], p = 0.008). WA%
correlated with greater BMI (r = 0.55, p < 0.001) and volume of adipose tissue (subcutaneous, r = 0.40; p < 0.001;
mediastinal, r = 0.25; p = 0.005). Multivariable regression found the COPD phenotype associated with greater age
and pack-years smoking; the asthma phenotype with younger age, female gender, smoking history, and lower
adiponectin levels; and greater WA% with greater BMI, younger age, higher soluble CD163, and higher CD4 counts.
Conclusions: Adiposity and adipose-related inflammation are associated with an asthma phenotype, but not a
COPD phenotype, of obstructive lung disease in HIV-infected persons. Airway wall thickness is associated with
adiposity and inflammation. Adipose-related inflammation may play a role in HIV-associated asthma.
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Background
Obstructive lung disease, encompassing many pheno-
types of both fixed and reversible airflow obstruction, is
common in HIV-infected persons [1–6]. Chronic ob-
structive pulmonary disease (COPD) in the HIV-infected
population is accelerated in smokers and those with
poor control of the viral load [1, 3, 7, 8]. Asthma is an-
other commonly diagnosed chronic pulmonary disease
in HIV-infected persons [9, 10]. Despite the prevalence
of COPD and asthma in HIV-infected persons, little is
known about their pathogenesis in this population.
Obesity influences the development of both COPD
and asthma in the HIV-uninfected population. Obesity is
more prevalent in individuals with mild COPD com-
pared to the general population, however, the causal na-
ture of the relationship between obesity and COPD is
unclear [11, 12]. Obesity, central adiposity, and aspects
of the metabolic syndrome have been implicated in the
pathogenesis of the adult-onset phenotype of asthma
[13–17]. Inflammation related to visceral adipose tissue
is thought to drive this association [18]. We have previ-
ously shown that doctor-diagnosed asthma in HIV is
frequently adult-onset, associated with inflammatory
markers common in chronic HIV infection, and 2.5
times more likely in obese compared to normal weight
HIV-infected persons [9].
Metabolic effects of HIV and highly-active antiretroviral
therapy (HAART) that lead to central adiposity and alter-
ations in inflammation may be relevant to the pathogen-
esis of airway obstruction in HIV [19, 20]. Long-term HIV
infection is associated with chronic inflammation and
macrophage activation, measured by high-sensitivity C-
reactive protein (CRP) and soluble CD163 (sCD163), re-
spectively [21–26]. Increased central adiposity is associ-
ated with the alteration of systemic adipokine profiles,
including higher leptin (a pro-inflammatory cytokine) and
lower adiponectin (an anti-inflammatory cytokine). Adi-
ponectin is lower in HIV-infected persons and in chronic
inflammation [27]; and reduced levels of adiponectin have
been implicated in several HIV-associated co-morbidities
such as cardiovascular disease and neurocognitive dys-
function [28–30]. In the HIV-uninfected population, levels
of adiponectin are lower in asthma and paradoxically
higher in COPD [31]. The relationship of adiponectin in
HIV-associated obstructive lung disease is unknown.
Obstructive lung disease can manifest subjectively as
pulmonary symptoms or objectively as pulmonary func-
tion changes or airway remodeling detectable on com-
puted tomography (CT) scan [32–34]. Asthma is often
diagnosed by doctors based on episodic, recurrent pul-
monary symptoms, such as wheezing. Pulmonary symp-
toms are more common in HIV-infected individuals with
doctor-diagnosed asthma than those without asthma [9].
Airway wall thickening correlates with asthma severity,
airflow obstruction, and histopathological changes related
to asthma [35–37]. Airway remodeling quantitatively mea-
sured by CT scan has not been assessed in HIV-infected
persons.
In this study, our primary objective was to determine
the relationship of adiposity and adipose-related inflam-
mation with obstructive lung disease phenotypes in
HIV-infected persons. Our secondary objective was to
determine the relationship of adiposity and its associated
inflammation with airway remodeling, as measured by
airway wall thickness on CT imaging, in HIV-infected
persons. We hypothesized that visceral (mediastinal) adi-
pose tissue and adipose-associated inflammatory markers
(adiponectin and IL-6) would be associated with airway
remodeling and the asthma phenotype of airflow obstruc-
tion and no association with the COPD phenotype of air-
flow obstruction, in HIV-infected persons.
Methods
Participants
This study was a cross-sectional secondary analysis of
individuals with documented HIV infection who were
18 years of age or older, recruited between July 1, 2007
and April 30, 2010 from the HIV/AIDS clinic at the Uni-
versity of Pittsburgh Medical Center using posted adver-
tisements and by contacting patients in a research
registry. Exclusion criteria included any contraindication
to pulmonary function testing and those with increased
respiratory symptoms or fevers within the prior 4 weeks
to exclude active pulmonary infection. Participants who
completed a CT scan of the chest in the established co-
hort were included in this study. A description of the
group and pulmonary function data from the primary
analysis has been published previously [2, 9]. Partici-
pants signed written informed consent, and the Univer-
sity of Pittsburgh IRB approved the protocol.
Data collection
Demographic and clinical data, including age, gender,
race, smoking status, and illicit drug use were collected
through standardized interviews by research coordina-
tors, and if unable to obtain, were then collected
through a review of the medical record. A modified ver-
sion of the American Thoracic Society (ATS) Division of
Lung Diseases questionnaire was used to collect infor-
mation on respiratory symptoms [38]. Participants com-
pleted the questionnaire on the same day as blood
collection, pulmonary function testing, and CT imaging.
A prior diagnosis of asthma was ascertained by asking
participants if their doctor had ever told them they had
asthma (doctor-diagnosed asthma), in addition to several
other pulmonary-related diseases such as COPD or sar-
coidosis [9].
Barton et al. BMC Pulmonary Medicine  (2016) 16:111 Page 2 of 10
Metabolic, immunologic and serologic parameters
Height and weight were measured to calculate BMI. In-
duced sputum samples were collected for sputum cell
counts [39]. Peripheral blood samples were collected at
the time of enrollment, and serum or plasma aliquots
were stored at -80C ranging from 2 to 6 years and
assayed following a single thaw. Markers of inflamma-
tion (interleukin [IL-6], high-sensitivity C-reactive pro-
tein [CRP]), monocyte/macrophage activation (sCD163)
and the adipokine adiponectin were assayed using ELISA
(R&D Systems; Minneapolis, MN). Total IgE was also
measured in the clinical laboratory to assess for an asso-
ciation between allergic/atopic measures and prevalent
airway obstruction phenotypes. Leptin was not measured
because blood samples were obtained in a non-fasting
state. The CD4+ T-lymphocyte cell count and the plasma
HIV ribonucleic acid (RNA) level within the prior three
months were obtained from medical record review.
Pulmonary function testing
All participants completed pre- and post-bronchodilator
spirometry (480 μg of albuterol administered through a
spacer from a metered-dose inhaler) and single breath
diffusing capacity for carbon monoxide (DLCO) in ac-
cordance with ATS standards [40, 41]. The percent pre-
dicted forced expiratory volume in 1 second (FEV1) and
forced expiratory capacity (FVC) were calculated using
the Hankinson prediction equations [42]. DLCO percent
predicted was determined using equations from Neas et al
and corrected for hemoglobin and carboxyhemoglobin [43].
Imaging parameters
CT of the chest was used to determine airway wall thick-
ness (WA%) in the smallest one-third of measurable air-
ways. We used a fully automated computer scheme to
detect and quantify airway sections depicted in axial sec-
tion of the CT examination as previously described [44].
Mediastinal (a surrogate for visceral adipose tissue in
the chest) and subcutaneous adipose volumes were deter-
mined using commercially available software (sliceOmatic,
Tomovision; Magog, Canada). The non-contrast chest CT
scans, collected as part of the parent study [45], were
processed with a standard algorithm in 2.5 mm thickness.
Adipose tissue was defined as voxels in Hu range of -190
to -30 [46]. The subcutaneous region included this Hu
range extending from skin to fascia circumferentially. The
borders of the mediastinum were defined laterally by the
edge of the most lateral mediastinal structure (superior
vena cava, right atrium, left ventricle, descending aorta,
and main pulmonary artery), anteriorly by the sternum,
and posteriorly by the vertebral body or the descending
aorta, whichever was the more anterior structure. The su-
perior margin of the mediastinum was defined by the first
slice inferior to the aortic arch, and the inferior margin
was defined by the most inferior slice where the dia-
phragm does not touch the heart.
To determine the inter-reader reliability of adipose
measures, adipose tissue measurements from a subset of
CT scans [10] were measured independently by two
different investigators (JHB, MRG), blinded to patient
characteristics.
Statistical analysis
Participants were classified as having a COPD phenotype
of airflow obstruction (post-bronchodilator FEV1/FVC
less than the lower limit of normal – below the 95 %
confidence interval) or an asthma phenotype of airflow
obstruction (either doctor-diagnosed asthma or a bron-
chodilator response on pulmonary function testing in ac-
cordance with ATS standards) [47]. We used this
composite of doctor-diagnosed asthma or bronchodila-
tor responsiveness because the pulmonary function test-
ing was done for research purposes and did not include
provocation testing, so participants with treated and
well-controlled asthma may not have had airflow ob-
struction or reversibility at the time of the study visit.
Participants with overlapping definitions of airflow ob-
struction were included in both the COPD and asthma
groups for analysis.
Participant characteristics and measures were summa-
rized for all participants and compared between those
with and without the COPD phenotype or the asthma
phenotype of airflow obstruction. Data were normalized
using logarithmic or square root transformation if neces-
sary. Parametric testing was performed with t-test, and
ranksum test was used for non-parametric comparisons.
Categorical and dichotomous variables were compared
between those with and without the COPD phenotype
or the asthma phenotype of airflow obstruction using
chi-square test. Pearson correlation coefficients were
used to determine correlations between WA% and lung
function. To determine inter-reader reliability of CT adi-
pose measures, Lin’s concordance correlation coeffi-
cients were calculated for both subcutaneous and
mediastinal adipose tissue measures. Multivariable logis-
tic regression was performed to determine if participant
characteristics (age, gender, race, BMI, smoking status,
viral load), adipose measures (subcutaneous and visceral
adipose volumes), and inflammatory markers (CRP, adi-
ponectin, IgE) were independently associated with the
COPD phenotype or the asthma phenotype of airflow
obstruction. Linear regression was used to determine as-
sociations between airflow obstruction and WA% with
the same series of variables used in the logistic regres-
sion including participant characteristics, CT adipose
measures, and inflammatory markers. Stepwise regres-
sion was used for both linear and logistic model selec-
tion, including variables significant at a level of p < 0.1 in
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univariate analyses. Logistic models were additionally
tested for fit with Hosmer-Lemeshow goodness-of-fit
test [48]. Statistical analyses were conducted using
StataSE version 13 (StataCorp LP, College Station, TX).
Results
A total of 121 HIV-infected participants were evaluated.
Overall, the mean (SD) age of all participants was 45.1
(9.8) years, and the majority were men (67.8 %) with a
history of smoking (82.6 %) (Table 1). Most participants
were on antiretroviral therapy (ART) (87.6 %) with a
mean CD4 count of 599.1 cells/μL, and 84 (69.5 %) had
an HIV RNA viral level <50 copies/mL. Twenty-three
(19 %) participants had the COPD phenotype of airflow
obstruction. Thirty-three (27 %) participants were classi-
fied as having the asthma phenotype of airflow obstruc-
tion; 25 of them had doctor-diagnosed asthma, six of
whom also had a bronchodilator response, and eight
participants had a bronchodilator response without prior
doctor-diagnosed asthma. Twelve (10 %) participants fit
both definitions of the COPD and asthma phenotypes,
and were included in both groups for analysis.
Participant characteristics differed between those with
and without the COPD phenotype of airflow obstruc-
tion. Those with the COPD phenotype were older, had
heavier smoking history as measured by pack-years, and
greater intravenous drug use (Table 1). BMI did not dif-
fer between those with and without the COPD pheno-
type of airflow obstruction (mean [SD] 27.0 kg/m2 [7.9]
vs. 27.8 kg/m2 [6.1], p = 0.59) (Fig. 1). Participant demo-
graphics were similar between those with and without
the asthma phenotype of airflow obstruction, except for
BMI (mean [SD] 30.7 kg/m2 [8.1] vs. 26.5 kg/m2 [5.3], p =
0.008), and female sex (n, 15 vs. 24, p = 0.06).










Age, mean (SD) 50.4 (5.7) 43.9 (10.1) <0.001 43.0 (9.5) 46.0 (9.8) 0.14
Female, n (%) 6 (26.1) 33 (33.7) 0.48 15 (45.5) 24 (27.3) 0.06
African American, n (%) 13 (56.5) 53 (54.1) 0.83 21 (63.6) 43 (48.9) 0.43
BMI (kg/m2), mean (SD) 27.0 (7.9) 27.8 (6.1) 0.58 30.7 (8.1) 26.5 (5.3) 0.008
Smoke status, n (%) 0.18 0.13
Never 1 (4.4) 20 (20.4) 2 (6.1) 19 (21.6)
Former 7 (30.4) 24 (24.5) 21 (23.9) 10 (30.3)
Current 15 (65.2) 54 (55.1) 21 (63.6) 48 (54.6)
Pack-years smoked, median (range) 20.0 (0-102) 9.8 (0-45) <0.001 13.5 (0-102) 10.8 (0-75) 0.33
Intravenous drug use (ever), n (%) 3 (13.0) 3 (3.1) 0.05 1 (3.0) 5 (5.7) 0.99
Cocaine use (ever), n (%) 5 (21.7) 23 (23.5) 0.86 5 (15.2) 23 (26.1) 0.20
Marijuana use (ever), n (%) 9 (39.1) 56 (57.1) 0.12 15 (45.5) 50 (56.8) 0.26
HAART use, n (%) 21 (91.3) 85 (86.7) 0.55 28 (84.9) 78 (88.6) 0.57
CD4 count (cells/μl), mean (SD) 578.6 (270.4) 603.5 (339.6) 0.75 596.7 (299.1) 599.9 (338.6) 0.96
HIV RNA level <50copies/mL, n (%) 16 (69.6) 68 (69.4) 0.99 19 (57.6) 65 (73.9) 0.08
Doctor-diagnosed asthma 8 (34.8) 17 (17.4) 0.99 25 (75.8) 0 na
Bronchodilator response 6 (26.1) 8 (8.2) 0.02 14 (42.4) 0 na
Cough 9 (39.1) 26 (26.5) 0.23 14 (42.4) 21 (23.9) 0.05
Phlegm 9 (39.1) 38 (38.8) 0.98 14 (42.4) 33 (37.5) 0.62
Wheeze 12 (52.2) 31 (31.6) 0.06 19 (57.6) 24 (27.3) 0.002
Dyspnea 10 (43.5) 35 (35.7) 0.49 14 (42.4) 31 (35.2) 0.47
pre-BD FEV1 %pred, mean (SD) 72.6 (19.0) 95.8 (16.7) <0.001 77.7 (20.6) 96.5 (16.2) <0.001
pre-BD FEV1/FVC, mean (SD) 0.61 (0.09) 0.78 (0.06) <0.001 0.69 (0.12) 0.77 (0.08) <0.001
post-BD FEV1/FVC, mean (SD) 0.62 (0.08) 0.81 (0.06) <0.001 0.73 (0.12) 0.80 (0.08) 0.003
post-BD FEV1/FVC < LLN, n (%) 23 (100) 0 (0) na 12 (36.4) 11 (12.5) 0.003
DLco % predicted, mean (SD) 0.57 (0.15) 0.68 (0.13) <0.001 0.63 (0.13) 0.67 (0.14) 0.13
Abbreviations: SD Standard deviation, BMI Body Mass Index, HAART Highly active antiretroviral therapy, BD Bronchodilator, FEV1 Forced expiratory volume in
1 second, FVC Forced vital capacity, %pred Percent predicted, LLN Lower limit of normal, DLco Diffusion capacity of the lung for carbon monoxide
aAsthma phenotype is defined by a history of doctor-diagnosed asthma or a bronchodilator response during pulmonary function testing (Increase in FEV1 or FVC
of greater than 200 ml and 12 %)
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Those with the COPD phenotype had lower pre- and
post-bronchodilator FEV1 %predicted and FEV1/FVC as
expected by definition, compared to those without COPD.
The participants with the asthma phenotype of obstruc-
tion had lower pre-BD FEV1 (78 %[21] vs. 97 %[16]; p =
<0.001) and pre-BD FEV1/FVC (69 %[12] vs. 77 %[8]; p =
<0.001) compared to those without asthma. DLCO was
moderately reduced amongst all participants (mean,
66 %); however, it was lower in participants with the
COPD phenotype compared to those without COPD
(57 %[15] vs. 68 %[13], p = <0.001). DLCO was no different
in those with the asthma phenotype of obstruction com-
pared to those without asthma (63 %[13] vs. 67 %[14], p =
0.13) (Fig. 1).
Several inflammatory markers were different between
the two phenotypes of airflow obstruction (Table 2).
CRP levels were higher in participants with both pheno-
types of airflow obstruction (COPD p = 0.04, asthma p =
0.04) versus those without airflow obstruction. The total
IgE level was elevated in the asthma phenotype group of
airflow obstruction (p = 0.03); however, there was no dif-
ference in the number of participants with elevated spu-
tum eosinophils. Adiponectin tended to be lower in the
asthma phenotype group compared to those without
asthma (p = 0.07). There was no difference in the level of
sCD163 amongst all participants. There was no differ-
ence in the level of IL-6 between those with or without
COPD, however, those with the asthma phenotype of
Fig. 1 Mean and standard deviation (error bar) of body mass index (BMI) (a), diffusing capacity of carbon monoxide (DLCO) % predicted (b), and
wall area % (c) in those with and without a COPD phenotype of airflow obstruction (post-bronchodilator forced expiratory volume at 1 second/
forced vital capacity less than the lower limit of normal) and in those with and without an asthma phenotype of airflow obstruction (doctor-
diagnosed asthma or bronchodilator response)










Sputum eosinophils >1.53 %, (n = 108)b 3 (13.6) 8 (9.3) 0.55 5 (16.1) 6 (7.8) 0.20
Sputum neutrophils (%), mean (SD) 55.9 (19.6) 50.6 (19.6) 0.27 50.0 (22.4) 52.4 (18.5) 0.57
C-reactive protein (mg/L), median (range)
(n = 117)
3.4 (0-74.2) 1.1 (0-107.6) 0.04 2.3 (0-77.6) 1.1 (0-107.6) 0.04
IgE level (IU/mL) median (range) (n = 116) 33.8 (2.2-1359.0) 41.5 (0.8-2758.5) 0.60 83.9 (5.1-1447.0) 28.7 (0.8-2758.5) 0.03
Soluble CD163 (ng/mL), median (range)
(n = 103)
887.9 (381.5-1999.3) 670.0 (180.1-2381.5) 0.22 726.9 (324.1-2193.1) 682.5 (180.1-2381.5) 0.11
IL-6 >median, n (%) (n = 98) 11 (64.7) 38 (46.9) 0.18 19 (67.9) 30 (42.9) 0.03
Adiponectin (ng/mL), median (range)
(n = 115)
5038 (0-14590) 2822 (0-22611) 0.10 2195 (0-12663) 3713 (0-22611) 0.07
Wall area % (n = 117), mean (SD) 47.6 (4.4) 47.9 (5.7) 0.84 51.0 (4.7) 46.8 (5.3) <0.001
SubQ adipose volume (cm3), median (range)c 22.9 (3.4-66.8) 26.8 (2.9-85.1) 0.30 33.3 (4.0-85.1) 22.1 (2.9-77.7) 0.004
Mediastinal adipose volume (cm3), median
(range)c
3.3 (1.8-13.9) 4.0 (1.1-13.5) 0.40 3.9 (1.4-13.9) 4.0 (1.1-11.6) 0.33
Mediastinal/SubQ, median (range) 0.19 (0.08-0.63) 0.17 (0.04-0.62) 0.47 0.15 (0.06-0.58) 0.13 (0.04-0.63) 0.02
Abbreviations: SD Standard deviation, IQR interquartile range, IL Interleukin, IFN Interferon, SubQ Subcutaneous
aAsthma phenotype is defined by a history of doctor-diagnosed asthma or a bronchodilator response during pulmonary function testing
bSputum eosinophil count of 1.53 % defined as the upper limit of normal
cAdipose volume is standardized by dividing per 5 mm measured in the z-axis
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obstruction had higher IL-6 levels compared to those
without asthma (p = 0.03).
There was excellent inter-reader reliability for subcuta-
neous (r = 0.955; p < 0.001) and mediastinal (r = 0.995; p <
0.001) adipose measures. There was no difference in the
volumes of adipose tissue in the mediastinum or the sub-
cutaneous regions of those with and without the COPD
phenotype of obstruction (Table 2). Participants with the
asthma phenotype of obstruction had a greater volume of
subcutaneous adipose tissue (33.3 cm3 vs. 22.1 cm3, p =
0.004), but no difference in the volume of mediastinal adi-
pose tissue compared to those without asthma (3.9 cm3
vs. 4.0 cm3, p = 0.33).
BMI and CT adipose measurements correlated with sev-
eral markers of inflammation. Adiponectin correlated in-
versely with BMI (r = -0.23, p = 0.01), and more strongly
with mediastinal adipose tissue (r = -0.41, p < 0.001) than
subcutaneous tissue (r = -0.19, p = 0.04)(data not shown).
Mediastinal adipose tissue correlated inversely with
IgE (r = -0.19, p = 0.04)(data not shown). Both BMI
(mean [SD], 30.1 kg/m2 [8.2] vs. 25.7 kg/m2 [4.0]; p =
0.001) and subcutaneous adipose tissue volume (mean
(SD) 17.4√cm3/slice (5.6) vs. 14.6√cm3/slice (4.8); p =
0.008) were greater with high IL-6 (data not shown).
There was no correlation between adipose tissue and CRP
or sCD163 (data not shown).
Airway wall thickness (WA%) did not differ between
those with and without the COPD phenotype of obstruc-
tion, but was greater in the group with the asthma
phenotype of airflow obstruction (51.0 % vs. 46.8 %; p <
0.001) (Fig. 1). Greater WA% was associated with lower
pre-BD FEV1 (r = -0.19; p = 0.04); there was no associ-
ation between WA% and pre-BD FEV1/FVC ratio or
DLCO (data not shown). Greater WA% was associated
with BMI, as well as both subcutaneous and mediastinal
adipose volumes (Fig. 2). Greater WA% was associated
with symptoms of wheezing (p = 0.02) and tended to be
associated with phlegm production, but was not associ-
ated with cough or dyspnea (data not shown).
We performed multivariable regression models to
identify factors associated with the COPD phenotype of
airflow obstruction, the asthma phenotype of obstruc-
tion, and WA% (Table 3). A list of all variables included
in the models can be found in the Methods section. The
COPD phenotype was associated with older age and lon-
ger smoking history. The asthma phenotype was associ-
ated with the female sex, younger age, smoking history,
and lower adiponectin values. Greater WA% was associ-
ated with greater BMI, younger age, higher sCD163, and
higher CD4 counts. People who smoked cigarettes or
used cocaine had lower WA%.
Discussion
This study demonstrates that there are unique associa-
tions that may be contributing to the pathogenesis of
two airway obstruction phenotypes in HIV-infected per-
sons. We found that the COPD phenotype of airflow ob-
struction was associated with heavier smoking and older
age. In contrast, the asthma phenotype of airflow ob-
struction was associated with the female sex, younger
age, smoking history, and lower adiponectin levels.
These findings suggest that, while there is some degree
of overlap in the two phenotypes, the association of adi-
ponectin, an important adipose-related mediator of in-
flammation, with the asthma phenotype of obstruction
may be mechanistically important in HIV-associated
asthma.
Asthma has several phenotypes of disease in the HIV-
uninfected population and may, similarly, have several
phenotypes in the HIV-infected population. Similar to
the general population, there is strong evidence that the
allergic phenotype of asthma is present, with elevated
total IgE. Additionally, a subset of asthma in HIV may
represent the adult-onset, obesity-mediated phenotype.
Fig. 2 Wall area thickness correlates with measures of adiposity including body mass index (BMI) (a), and the volumes of subcutaneous (b) and
mediastinal (c) adipose tissue in a group of HIV-infected persons
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We have previously shown an association between
asthma and BMI in HIV [9], suggesting that the increas-
ingly recognized adult-onset obesity phenotype might
also be more prevalent in the HIV-infected population
[49, 50]. Our univariate analyses highlight the significant
association of increasing volume of subcutaneous tissue
with the asthma phenotype of airflow obstruction more
than mediastinal adipose tissue as we had hypothesized.
Increased deposition of visceral adipose tissue is more
strongly associated with metabolic dysregulation and in-
flammation in the HIV-uninfected population; therefore,
subcutaneous adipose tissue in the HIV-infected popula-
tion may be playing a more significant role in asthma
pathogenesis. This study also demonstrated a strong cor-
relation between BMI and adipose measures, both sub-
cutaneous and mediastinal, with increased airway wall
thickness, a marker of airway inflammation and remod-
eling. In multivariable analysis, there was a significant
correlation between adiponectin and the asthma pheno-
type of obstruction, an adipose-mediated inflammatory
marker. Several studies have shown a link between adi-
ponectin and asthma in obese asthmatics compared to
non-obese asthmatics, but this association has not previ-
ously been reported in HIV [14, 17, 18].
Alternatively, HIV-associated asthma may be related
to chronic HIV-associated inflammation. HIV leads to
immune activation and chronic inflammation, with ele-
vated levels of IL-6, CRP, and D-Dimer compared to the
general population [21–24]. In our study, CRP tended to
be associated with greater airway obstruction. We and
others have shown that serum IL-6 is associated with
adiposity, suggesting that there is increased inflamma-
tion related to obesity as well [51]. In our multivariable
regression model, airway remodeling was associated with
greater BMI, higher CD4 counts, and higher sCD163
levels, suggesting that macrophage activation from
chronic immune activation [25, 26] and obesity may
both play a role in airway remodeling, but the degree to
which they are related is unclear [52, 53].
Inflammation related to lipodystrophy is an important
factor causing HIV-associated non-AIDS diseases. Sev-
eral other HIV co-morbidities, including cardiovascular
disease and neurocognitive dysfunction, have been associ-
ated with increased adiposity and inflammation [28–30].
Our findings mirror these associations, suggesting that
adipose-related factors, chronic inflammation, and macro-
phage activation are probable contributors to the in-
creased disease burden of certain types of obstructive lung
disease in HIV infection.
It is important to note the global reduction in the
DLCO and high smoking rate amongst all participants
within this cohort of HIV-infected persons. Diffusion
impairment is commonly reduced in the HIV-infected
population compared with the general population, even
in never smokers [3, 5]. A significantly lower DLCO was
a feature of the COPD phenotype, but not the asthma
phenotype, confirming that the asthma phenotype is a
unique phenotype of airflow obstruction within this
population. This phenotype may be related to different
factors than those that drive diffusion impairment and
COPD. Furthermore, airway wall thickness did not cor-
relate with DLCO, only with BMI and FEV1.
This cohort of HIV-infected persons is representative
of the HIV population in the post-ART era, with the ma-
jority of participants well-controlled on ART with an
average CD4 count > 500cells/μL and HIV RNA levels
<50copies/mL. Although there was a high prevalence of
tobacco and drug use in this cohort, which may lead to
alterations in some of the measured inflammatory
markers, these risk factors did not differ between those
with and without airflow obstruction, and are not
markedly higher than the U.S. HIV population esti-
mates [54, 55]. Another strength of this study is that
we used a variety of methods to assess adiposity and
its correlation with asthma, including clinical data,
radiographic data, and serum biomarkers.
Our study has limitations that need to be considered.
It is cross-sectional, and therefore, it is not possible to
attribute cause and effect, particularly between obesity
and asthma. However, many studies showing an associ-
ation between obesity and asthma have been corrobo-
rated in longitudinal studies and even an intervention
study [56–58]. We defined the asthma phenotype of
Table 3 Multivariable analysis models of pulmonary function
abnormalities and airway wall thickness with participant
characteristics and inflammatory markers
COPD phenotype OR (95 % CI) p-value
Pack-years smoked, per pack-year 1.05 (1.02-1.08) p = 0.003
Age, per year 1.07 (1.01-1.14) p = 0.03
Asthma phenotype OR (95 % CI) p-value
Female vs. male 5.48 (1.78-16.9) p = 0.003
Age, per year 0.95 (0.91-0.99) p = 0.04
Smoking history, per pack-years 1.03 (1.00-1.06) p = 0.04
Adiponectin, per ln(ng/mL) 0.98 (0.96-0.99) p = 0.01
Airway wall thickness Coef. (95 % CI) p-value
Body mass index, per kg/m2 0.39 (0.23-0.54) p < 0.001
Age, per year -0.13 (-0.22-0.05) p = 0.003
Former smoker vs. never smoker -3.76 (-6.34-1.18) p = 0.005
Current smoker vs. never smoker -3.21 (-5.57-0.86) p = 0.008
Ever used cocaine vs. never used cocaine -2.35 (-4.60-0.10) p = 0.04
soluble CD163, per ln (ng/mL) 2.95 (1.26-4.64) p = 0.001
CD4+ T-cells, per 100 cell/μL 0.27 (0.01-0.52) p = 0.04
Abbreviations: OR Odds ratio, Coef Coefficient, CI Confidence interval, CRP
C-reactive protein, FEV1 Forced expiratory volume in 1 second, FVC Forced vital
capacity, ln natural logarithm
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obstruction as having either doctor-diagnosed asthma or
a bronchodilator response with pulmonary function test-
ing, and only 42.4 % of those with doctor-diagnosed
asthma had a bronchodilator response. The absence of
bronchodilator response could be attributed to treated
or well-controlled asthma not manifested on pulmonary
function testing at the time of the study. The composite
definition of the asthma phenotype may lead to hetero-
geneity in our study group, but we have found pulmon-
ary function and biomarker similarities in participants
fitting this composite definition [9]. Bronchodilator re-
sponsiveness is more classically seen in asthma; however,
bronchodilator reactivity can be seen with fixed airflow
obstruction, and in fact, may represent a sub-phenotype
of COPD (asthma-COPD overlap syndrome (ACOS) ra-
ther than asthma. Despite our inclusion of the overlap
participants in both the COPD and asthma airflow ob-
struction groups during analysis, there was a striking dif-
ference between participant characteristics suggesting
that participants with the overlap are a unique pheno-
type. We measured mediastinal adipose tissue because
we had access to chest CT scans done as part of the par-
ent study [45]. Mediastinal adipose tissue volume has
been shown in other populations to have similar charac-
teristics to abdominal visceral adipose tissue and to cor-
relate with subclinical cardiovascular disease in HIV
[59]; however, this measure may not be an adequate re-
flection of visceral adiposity. Dedicated abdominal CT
scans may be more useful in this assessment, but were
not available. Also, we used adiponectin as our adipose-
mediated inflammatory marker as these were non-
fasting blood samples; however, leptin has been more
strongly correlated with obesity-related inflammation
and asthma. Mediastinal adipose tissue and adiponectin
have been correlated with cardiovascular disease in HIV,
supporting the validity in these measures as important
markers in adipose-mediated inflammation. Finally, the
level of associations that were seen in this study were in-
teresting and novel, albeit overall low to moderate in
biological associations between the variables.
Conclusions
In conclusion, there are different features associated with
the COPD phenotype versus the asthma phenotype of ob-
structive lung disease in HIV-infected persons. Adipose-
related factors, chronic inflammation, and macrophage
activation are probable contributors to the increased dis-
ease burden of obstructive lung disease in HIV infection.
These differences point out that there is likely not a single
mechanism of airway obstruction in HIV, and a better un-
derstanding of the airway disease phenotypes and their
pathogenesis is needed to optimize treatment of airflow
obstruction in HIV.
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